マーケットレポート詳細
創薬向け人工知能(AI)の世界市場：AI技術別、用途別2027年予測
Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts ( 2022 - 2027 )
- 出版元：MarketsandMarkets
出版元について - 発行年：2022年6月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文193ページになります。
- 商品コード：MAM2960
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
創薬向け人工知能(AI)の世界市場規模は2022年で6億ドル、2027年に40億ドル、市場の平均年成長率は45.7%に到達する見込みです。
レポートは創薬向け人工知能(AI)の世界市場について2027年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（技術別市場、用途別市場、等）を中心に構成されています。また競合状況、主要企業情報（12社）、市場ダイナミクス、エコシステムなどの分析も加味し、創薬向け人工知能(AI)市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆創薬向け人工知能(AI)の世界市場予測2020-2027年
・市場規模(US$)
◆オファリング別、市場-2027年
・ソフトウェア
・サービス
※(市場規模US$)
◆技術別、市場-2027年
機械学習
・ディープラーニング
・教師あり学習
・強化学習
・教師なし学習
・その他機会学習技術
その他技術
※(市場規模US$)
◆用途別、市場-2027年
・イムノオンコロジー
・神経変性疾患
・循環器系疾患
・代謝性疾患
・その他用途
※(市場規模US$)
◆エンドユーザー別、市場-2027年
・製薬/バイオテクノロジー企業
・医薬品開発業務受託機関(CRO)
・研究センター及び学術/政府機関
※(市場規模US$)
◆主要国地域別市場-2027年
北米
・米国、カナダ、メキシコ
欧州
・英国、ドイツ、フランス、イタリア
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※国地域別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・バリューチェーン分析
・ファイブフォース分析
・エコシステム
・技術分析
・ケーススタディ分析
・競合状況
◆創薬向け人工知能(AI)の主要企業プロフィール動向
・MICROSOFT
・NVIDIA
・EXSCIENTIA
・GOOGLE
・BENEVOLENTAI
・NUMEDII, INC.
・BERG, LLC
・ATOMWISE
・DEEP GENOMICS
・INSILICO MEDICINE
・SCHRÖDINGER, INC.
・IBM
（その他企業）
・CYCLICA INC.
・CLOUD PHARMACEUTICALS
・BIOAGE
・ENVISAGENICS
・TWOXAR, INC. (ARIA PHARMACEUTICALS)
・OWKIN, INC.
・XTALPI, INC.
・VERGE GENOMICS
・IKTOS
・EVAXION BIOTECH
・STANDIGM
・VALO HEALTH
・BIOVISTA
・BENCHSCI
（全193頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED 28
・ FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 2 RESEARCH DESIGN 31
2.2 SECONDARY SOURCES
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 PRIMARY SOURCES 34
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
2.3.2.1 KEY INDUSTRY INSIGHTS
2.4 MARKET SIZE ESTIMATION
・ FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
・ FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
・ TABLE 1 FACTOR ANALYSIS 40
・ FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022–2027)
・ FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
・ FIGURE 8 TOP-DOWN APPROACH 41
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 9 DATA TRIANGULATION METHODOLOGY
・ TABLE 2 MARKET SIZING ASSUMPTIONS
2.6 OVERALL STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
・ TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
3 EXECUTIVE SUMMARY
・ FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION)
・ FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
・ FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
・ FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
4 PREMIUM INSIGHTS
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW
・ FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS
4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021–2027)
・ FIGURE 15 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021)
・ FIGURE 16 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 17 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS 53
・ TABLE 4 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019−2021)
5.2.1.2 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS AND REDUCE TIME INVOLVED IN DRUG DEVELOPMENT
5.2.1.3 PATENT EXPIRY OF SEVERAL DRUGS
・ TABLE 5 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022
5.2.2 MARKET RESTRAINTS 55
5.2.2.1 SHORTAGE OF AI WORKFORCE AND AMBIGUOUS REGULATORY GUIDELINES FOR MEDICAL SOFTWARE
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 GROWING BIOTECHNOLOGY INDUSTRY
5.2.3.2 EMERGING MARKETS
5.2.3.3 FOCUS ON DEVELOPING HUMAN-AWARE AI SYSTEMS
5.2.3.4 GROWTH IN THE DRUGS AND BIOLOGICS MARKET DESPITE THE COVID-19 PANDEMIC
5.2.4 MARKET CHALLENGES 56
5.2.4.1 LIMITED AVAILABILITY OF DATA SETS
5.3 VALUE CHAIN ANALYSIS
・ FIGURE 19 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021)
5.4 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 6 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5 ECOSYSTEM
・ FIGURE 20 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
5.6 TECHNOLOGY ANALYSIS
5.7 PRICING ANALYSIS
5.8 BUSINESS MODELS
・ FIGURE 21 AI IN LIFE SCIENCES: BUSINESS MODELS
・ FIGURE 22 BENEFITS OF HYBRID BUSINESS MODELS
・ FIGURE 23 SPECIALIZATION OF AI COMPANIES OVER TIME
5.9 REGULATIONS
5.10 CONFERENCES AND WEBINARS
5.11 CASE STUDY ANALYSIS
5.11.1 CASE STUDY 1
5.11.2 CASE STUDY 2
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING
6.1 INTRODUCTION
・ TABLE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 67
6.2 SOFTWARE
6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH
・ TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 SERVICES
6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
・ TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 13 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 14 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 15 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
・ TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73
7.2 MACHINE LEARNING
・ TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020–2027 (USD MILLION)
・ TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 DEEP LEARNING
7.2.1.1 DEEP LEARNING ACCELERATES THE DISCOVERY PROCESS OF LIFE-SAVING DRUGS AND PRECISION MEDICINE
・ TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 SUPERVISED LEARNING
7.2.2.1 SUPERVISED LEARNING CAN BE APPLIED IN DRUG REPOSITIONING
・ TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 REINFORCEMENT LEARNING
7.2.3.1 INSILICO MEDICINE IS A PIONEER IN THE APPLICATION OF REINFORCEMENT LEARNING IN DRUG DISCOVERY
・ TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 UNSUPERVISED LEARNING
7.2.4.1 UNSUPERVISED LEARNING CAN BE MORE UNPREDIC・ TABLE THAN ALTERNATE MODELS
・ TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
・ TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 OTHER TECHNOLOGIES
・ TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION
8.1 INTRODUCTION
・ TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 IMMUNO-ONCOLOGY
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
・ TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT
・ TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 NEURODEGENERATIVE DISEASES
8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT
・ TABLE 52 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 53 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 54 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 55 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 CARDIOVASCULAR DISEASES
8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH
・ TABLE 56 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
・ TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 METABOLIC DISEASES
8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT
・ TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER APPLICATIONS
・ TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 67 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 68 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER
9.1 INTRODUCTION
・ TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI
・ TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
・ TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
・ TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROS
・ TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
・ TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS
・ TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
・ TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION
10.1 INTRODUCTION
・ TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
・ FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
・ TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 STRONG ECONOMY AND TREND OF EARLY ADOPTION OF TECHNOLOGIES ARE DRIVING MARKET GROWTH IN THE US
・ TABLE 91 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET
・ TABLE 92 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 111
・ TABLE 93 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 112
・ TABLE 94 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 95 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 112
10.2.2 CANADA
10.2.2.1 GROWING RESEARCH ON AI TECHNOLOGIES AND EMERGENCE OF NEW AI-BASED START-UPS WILL SUPPORT MARKET GROWTH IN CANADA
・ TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION) 113
・ TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 114
・ TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION) 114
10.2.3 MEXICO
10.2.3.1 GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH IN MEXICO
・ TABLE 100 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 101 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 102 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 103 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
・ FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
・ TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 UK
10.3.1.1 UK HOLDS THE LARGEST SHARE OF THE EUROPEAN MARKET
・ TABLE 109 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK
・ TABLE 110 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 111 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 GOVERNMENT SUPPORT AND FAVORABLE TRAINING PROGRAMS ARE KEY MARKET DRIVERS IN GERMANY
・ TABLE 114 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 STRONG GOVERNMENT SUPPORT AND FAVORABLE STRATEGIES & INITIATIVES TO DRIVE MARKET GROWTH IN FRANCE
・ TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 119 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 120 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 PRESENCE OF A STRONG PHARMACEUTICAL INDUSTRY IN ITALY TO DRIVE MARKET GROWTH
・ TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 REST OF EUROPE
・ TABLE 126 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 127 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 128 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 129 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
・ TABLE 130 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
・ TABLE 131 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 132 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 133 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 134 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 JAPAN DOMINATES THE APAC MARKET FOR AI IN DRUG DISCOVERY
・ TABLE 135 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 136 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 137 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 138 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 GROWING CMO MARKET AND CROSS-INDUSTRY COLLABORATIONS ARE FACTORS RESPONSIBLE FOR MARKET GROWTH IN CHINA
・ TABLE 139 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 140 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 141 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 142 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 STEADY ADOPTION OF AI TECHNOLOGIES WILL DRIVE MARKET GROWTH IN INDIA
・ TABLE 143 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 144 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 145 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 146 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
・ TABLE 147 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 148 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 149 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 150 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
・ TABLE 151 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
・ TABLE 152 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
・ TABLE 153 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
・ TABLE 154 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET
11.3 MARKET RANKING ANALYSIS
・ TABLE 155 AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021
11.4 COMPETITIVE BENCHMARKING
・ TABLE 156 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
・ TABLE 157 AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS
・ TABLE 158 AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STARS
11.5.2 EMERGING LEADERS 144
11.5.3 PERVASIVE PLAYERS 145
11.5.4 PARTICIPANTS
・ FIGURE 26 AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021
11.6 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS 146
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES 146
・ FIGURE 27 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
11.7 COMPETITIVE SITUATIONS AND TRENDS
・ TABLE 159 PRODUCT LAUNCHES
・ TABLE 160 DEALS
12 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS) *
12.1 KEY PLAYERS
12.1.1 MICROSOFT
・ TABLE 161 MICROSOFT: BUSINESS OVERVIEW 151
・ FIGURE 28 MICROSOFT: COMPANY SNAPSHOT (2020)
・ TABLE 162 MICROSOFT: DEALS
12.1.2 NVIDIA
・ TABLE 163 NVIDIA: BUSINESS OVERVIEW
・ FIGURE 29 NVIDIA: COMPANY SNAPSHOT (2022)
・ TABLE 164 NVIDIA: EXPANSIONS
・ TABLE 165 NVIDIA: DEALS
12.1.3 EXSCIENTIA
・ TABLE 166 EXSCIENTIA: BUSINESS OVERVIEW
・ FIGURE 30 EXSCIENTIA: COMPANY SNAPSHOT (2021)
12.1.4 GOOGLE
・ TABLE 167 GOOGLE: BUSINESS OVERVIEW
・ FIGURE 31 GOOGLE: COMPANY SNAPSHOT (2021)
12.1.5 BENEVOLENTAI
・ TABLE 168 BENEVOLENTAI: BUSINESS OVERVIEW
12.1.6 NUMEDII, INC.
・ TABLE 169 NUMEDII: BUSINESS OVERVIEW 167
12.1.7 BERG, LLC
・ TABLE 170 BERG, LLC: BUSINESS OVERVIEW 169
12.1.8 ATOMWISE
・ TABLE 171 ATOMWISE: BUSINESS OVERVIEW 171
12.1.9 DEEP GENOMICS
・ TABLE 172 DEEP GENOMICS: BUSINESS OVERVIEW
12.1.10 INSILICO MEDICINE 175
・ TABLE 173 INSILICO MEDICINE: BUSINESS OVERVIEW
12.1.11 SCHRÖDINGER, INC. 177
・ TABLE 174 SCHRÖDINGER: BUSINESS OVERVIEW
・ FIGURE 32 SCHRÖDINGER: COMPANY SNAPSHOT (2021)
12.1.12 IBM
・ TABLE 175 IBM: BUSINESS OVERVIEW
・ FIGURE 33 IBM: COMPANY SNAPSHOT (2022) 182
・ TABLE 176 IBM: DEALS
・ TABLE 177 IBM: OTHER DEVELOPMENTS
12.2 OTHER PLAYERS
12.2.1 CYCLICA INC.
12.2.2 CLOUD PHARMACEUTICALS
12.2.3 BIOAGE
12.2.4 ENVISAGENICS
12.2.5 TWOXAR, INC. (ARIA PHARMACEUTICALS)
12.2.6 OWKIN, INC.
12.2.7 XTALPI, INC.
12.2.8 VERGE GENOMICS
12.2.9 IKTOS
12.2.10 EVAXION BIOTECH 188
12.2.11 STANDIGM
12.2.12 VALO HEALTH
12.2.13 BIOVISTA
12.2.14 BENCHSCI
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS